InvestorsHub Logo
Followers 271
Posts 53174
Boards Moderated 3
Alias Born 08/16/2008

Re: None

Monday, 07/20/2020 10:30:19 AM

Monday, July 20, 2020 10:30:19 AM

Post# of 159
BTAI

Bioxcel Therapeutics Announces Phase 3 Trials Results Of Bxcl501 For Treatment Of Agitation In Patients With Schizophrenia And Bipolar Disorder
BY Reuters — 8:22 AM ET 07/20/2020

July 20 (Reuters) - BioXcel Therapeutics Inc (BTAI) BIOXCEL THERAPEUTICS ANNOUNCES PRIMARY AND SECONDARY ENDPOINTS MET IN TWO PIVOTAL PHASE 3 TRIALS OF BXCL501 FOR THE ACUTE TREATMENT OF AGITATION IN PATIENTS WITH SCHIZOPHRENIA AND BIPOLAR DISORDER

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BTAI News